At the conclusion of these activities, participants will be able to:

Early Detection of Prostate Cancer: AUA/SUO Guideline (2023)

1. Discuss the potential benefits, limitations, and controversies associated with prostate cancer screening.
2. Summarize the key recommendations provided in the AUA/SUO Guideline regarding early detection strategies for prostate cancer.
3. Analyze the implications of the AUA/SUO Guideline on clinical practice, shared decision-making, and patient counseling regarding early detection of prostate cancer.

Treatment Intensification for Advanced Prostate Cancer

1. Identify the latest developments in hormone therapy for advanced prostate cancer, including the use of novel treatments and combinations.
2. Discuss the concept of doublet and triplet therapy in advanced prostate cancer and its rationale in enhancing treatment efficacy.
3. Consider the challenges and future directions in implementing doublet and triplet therapy in clinical practice, including cost, accessibility, and patient selection.

Germline Testing and Novel Approaches to Targeting Genetic Mutations in Prostate Cancer

1. Identify the indications for germline testing in prostate cancer patients.
2. Explain how germline testing is used to identify genetic mutations in genitourinary (GU) cancers, specifically focusing on prostate cancer.
3. Analyze the potential advantages and challenges associated with using germline testing and targeted therapies in the management of prostate cancer.

Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer

1. Describe the importance of individualized treatment decision-making and shared decision-making in the management of intermediate and high-risk NMIBC.
2. Discuss the challenges associated with BCG shortage and its impact on patient care and treatment decisions.
3. Evaluate alternative intravesical therapies for NMIBC, such as chemotherapeutic agents (e.g., mitomycin C, gemcitabine), novel immunotherapies (e.g., intravesical pembrolizumab), and clinical trials.

Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer

1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment.
2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches.
3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up.

The Latest Breakthroughs in Immunotherapy for GU Cancers

1. Identify the newest immunotherapy drugs approved for prostate, bladder, and kidney cancer, including immune checkpoint inhibitors and other novel immunotherapies.
2. Discuss the clinical evidence supporting the use of these immunotherapy drugs in prostate, bladder, and kidney cancer, including data from pivotal clinical trials, response rates, and survival outcomes.
3. Evaluate the safety profile and potential immune-related adverse events associated with the newest immunotherapy drugs in GU cancers.

Germline Testing in GU Cancers – How I Do It

1. Differentiate between germline and somatic testing in the context of GU cancers, understanding the fundamental differences in the types of genetic alterations detected and their implications for patients and their families.
2. Describe the genetic counseling process and the importance of pre-test counseling to discuss the benefits, limitations, and potential implications of germline testing.
3. Evaluate the clinical significance and impact of germline testing results on treatment decisions, surveillance recommendations, and family management.

Novel Imaging for Genitourinary Cancers – Diagnostics and Theranostics

1. Review the latest clinical trials investigating the use of PET imaging agents in prostate, kidney, and urothelial cancer, including their diagnostic accuracy and impact on patient management.
2. Discuss the available PET imaging agents for prostate cancer, with a specific focus on PSMA (Prostate-Specific Membrane Antigen) PET imaging, including its mechanism of action and its potential for detection of primary tumors, lymph node metastases, and distant metastases.
3. Discuss the benefits of incorporating PET imaging, including PSMA PET, in guiding treatment decisions for GU cancers, such as its impact on treatment selection, treatment response assessment, and the potential for theranostic approaches.